<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6279">
  <stage>Registered</stage>
  <submitdate>2/04/2014</submitdate>
  <approvaldate>2/04/2014</approvaldate>
  <nctid>NCT02104856</nctid>
  <trial_identification>
    <studytitle>Bronchial Thermoplasty Global Registry</studytitle>
    <scientifictitle>Bronchial Thermoplasty (BT) Global Registry</scientifictitle>
    <utrn />
    <trialacronym>BT Registry</trialacronym>
    <secondaryid>E7086</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Asthma</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Alair System (Bronchial Thermoplasty)

Alair System (Bronchial Thermoplasty) - Asthma patients undergoing Bronchial Thermoplasty treatment with commercially available Alair device as per Directions For Use.


Treatment: devices: Alair System (Bronchial Thermoplasty)


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of patients who experience severe asthma exacerbations - The primary endpoint will be the proportion of patients who experience severe asthma exacerbations at 1 and 2 years following BT treatment with the Alair System.</outcome>
      <timepoint>2 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Asthma Quality of Life Questionnaire (AQLQ) score - Change from baseline in Asthma Quality of Life Questionnaire (AQLQ) scores will be summarized descriptively for Year 1 and Year 2 post-BT.</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Asthma Control Test (ACT) score - Change from baseline in Asthma Control Test (ACT) scores will be summarized descriptively for Year 1 and Year 2 post-BT.</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Emergency department visits for asthma symptoms - Will be summarized both by the incidence (percentage of subjects reporting at least one event) and event rates (events/subject/year) for 1 and 2 Years post-BT.</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hospitalizations for asthma symptoms - Will be summarized both by the incidence (percentage of subjects reporting at least one event) and event rates (events/subject/year) for 1 and 2 Years post-BT.</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Unscheduled office visits including urgent care visits for asthma symptoms. - Will be summarized both by the incidence (percentage of subjects reporting at least one event) and event rates (events/subject/year) for 1 and 2 Years post-BT.</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pre- and post-bronchodilator FEV1 - Pre- and post-bronchodilator FEV1 will be summarized for Year 1 and Year 2 post-BT treatment (% predicted and absolute value). Change from baseline will also be summarized.</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Respiratory Adverse Events - Separated by treatment period and post-treatment period</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Lung Volumes - Collected at sites where it is standard of care</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Diffusion Capacity - Collected at sites where it is standard of care</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Asthma maintenance medication use (Long Acting Beta Agonists, steroids etc.) - Collect asthma maintenance medications at all sites</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient satisfaction survey score - Two question survey collected at 12 month and 24 month annual visit</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Allergic skin test or RAST (perennial, seasonal, mold) - Collected at sites where it is standard of care</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Sputum eosinophils - Collected at sites where it is standard of care</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Exhaled nitric oxide (eNO) - Collected at sites where it is standard of care</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Methacholine challenge (Methacholine PC20) - Collected at sites where it is standard of care</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Patient is an adult aged 18 years or older and is scheduled to undergo BT treatment
             according to the Alair System DFU.

          2. Patient is able to read, understand, and sign a written Informed Consent to
             participate in the Registry and able to comply with the registry requirements.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Patient has any medical condition that would make them inappropriate for BT treatment,
        in the Investigator's opinion.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational [Patient Registry]</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>160</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>Macquarie University Private Hospital - North Ryde</hospital>
    <hospital>Royal Brisbane and Women's Hospital - Herston</hospital>
    <hospital>St. Andrews War Memorial Hospital - Spring Hill</hospital>
    <hospital>Peninsula Health - Frankston</hospital>
    <hospital>St. John of God Geelong Hospital - Geelong</hospital>
    <postcode>2109 - North Ryde</postcode>
    <postcode>4001 - Herston</postcode>
    <postcode>4000 - Spring Hill</postcode>
    <postcode>3199 - Frankston</postcode>
    <postcode>3220 - Geelong</postcode>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Prague</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bonn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Regensburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Ancona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Brescia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Mantova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Reggio nell Emilia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Cape Town</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Scotland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Boston Scientific Corporation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of this Registry is to collect real-world data on patients undergoing
      bronchial thermoplasty (BT) treatment.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02104856</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Robert Niven, MD</name>
      <address>Wythenshawe Hospital - University of Manchester</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>